Welcome to our dedicated page for Black Diamond Therapeutics news (Ticker: BDTX), a resource for investors and traders seeking the latest updates and insights on Black Diamond Therapeutics stock.
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) is a leading precision oncology medicine company headquartered in Cambridge, Massachusetts. Founded in 2014, the company focuses on the discovery and development of small molecule, tumor-agnostic therapies designed to target families of oncogenic mutations across various cancers.
The core of Black Diamond’s innovative approach lies in its proprietary Mutation-Allostery-Pharmacology (MAP) platform. This platform enables the identification and targeting of allosteric mutations in key cancer-related kinases, offering new therapeutic options for patients with limited treatments available.
The company’s lead product candidate, BDTX-189, is a potent inhibitor targeting non-canonical and oncogenic mutations of ERBB kinases, including the epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The development pipeline also includes BDTX-1535, an advanced fourth-generation EGFR inhibitor, and BDTX-4933, targeting KRAS, NRAS, and BRAF mutations in solid tumors.
Recent clinical updates highlight the potential of BDTX-1535 in treating non-small cell lung cancer (NSCLC) and glioblastoma (GBM), demonstrating efficacy against over 50 clinically relevant non-classical EGFR mutations and resistance mutations like C797S. This candidate is currently advancing through Phase 2 trials, with promising results expected in 2024.
Black Diamond Therapeutics has also established significant collaborations and partnerships to bolster its research and development efforts. These collaborations aim to enhance the understanding of mutation landscapes and accelerate the delivery of new therapies to patients.
For more information, visit Black Diamond Therapeutics.
Black Diamond Therapeutics (Nasdaq: BDTX) announced that its President and CEO, David M. Epstein, Ph.D., will present an overview of the company's MasterKey programs, including BDTX-1535 and BDTX-4933, during the Stifel 2023 Targeted Oncology Days on April 25, 2023, at 11:00 a.m. ET. The presentation will take place virtually, and a live webcast can be accessed on the company's investor relations website. Following the event, a replay will be available for 90 days.
Black Diamond is a clinical-stage precision oncology medicine company, focused on developing MasterKey therapies that target oncogenic mutations in genetically defined cancers. Their lead programs include BDTX-1535 for EGFR mutant-positive non-small cell lung cancer and glioblastoma multiforme, and BDTX-4933 targeting RAF mutations in solid tumors. The company uses its proprietary MAP drug discovery engine to analyze genetic data and validate MasterKey mutations.
Black Diamond Therapeutics (Nasdaq: BDTX) has announced the ongoing Phase 1 dose escalation study of BDTX-1535 targeting non-small cell lung cancer (NSCLC) with EGFR mutations and recurrent glioblastoma multiforme (GBM). Additionally, preclinical data for BDTX-4933 shows it effectively inhibits aberrant RAF signaling in models with BRAF and RAS mutations. The company presented findings at the 2023 AACR Annual Meeting, highlighting its MasterKey approach to oncology, which aims to address unmet needs in cancer treatment.
The Phase 1 study of BDTX-1535, initiated in 2022, is set to expand cohorts in 2023, while a Phase 1 trial for BDTX-4933 is scheduled for Q2 2023. The upcoming clinical updates are anticipated in the second half of this year.
Black Diamond Therapeutics (BDTX) reported its 2022 financial results, showing significant developments in its MasterKey pipeline. The company received FDA clearance for BDTX-4933 and is on track to provide a clinical update on BDTX-1535 in the second half of 2023. As of December 31, 2022, BDTX had $122.8 million in cash, enough to fund operations through Q3 2024. The company plans to initiate a Phase 1 clinical trial for BDTX-4933 in early 2023. R&D expenses decreased to $64.4 million, while net loss for 2022 was $91.2 million, improved from $125.6 million in 2021, indicating potential operational efficiencies.
Black Diamond Therapeutics (Nasdaq: BDTX) announced that its CEO, David M. Epstein, Ph.D., will present an update on the company’s advancements at the Cowen 43rd Annual Health Care Conference on March 6, 2023, at 12:50 p.m. ET in Boston, MA. The presentation will be accessible via a live webcast on the company’s investor relations page, with a replay available for 90 days post-event.
Black Diamond specializes in precision oncology, focusing on MasterKey therapies targeting oncogenic driver mutations in genetically-defined cancers, including its lead programs BDTX-1535 for EGFR mutant-positive non-small cell lung cancer and glioblastoma, and BDTX-4933 targeting RAF mutations.
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) will present an update on its progress at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 9:00 a.m. PT in San Francisco. CEO David M. Epstein will lead the presentation, focusing on the company’s advancements in precision oncology therapies targeting oncogenic driver mutations in genetically defined cancers. Black Diamond's pipeline includes clinical-stage programs BDTX-1535 and BDTX-4933, aiming to address significant unmet medical needs.
Black Diamond Therapeutics (Nasdaq: BDTX) announced the resignation of Chairman Robert A. Ingram for personal reasons. Mark Velleca, an existing Board member, has been appointed as the new Chairman. Ingram expressed confidence in the company's future, highlighting its robust pipeline and MAP drug discovery engine. Velleca shared enthusiasm for advancing Black Diamond's precision oncology mission, especially regarding ongoing clinical programs like BDTX-1535. Both leaders acknowledged the company's commitment to addressing significant unmet needs in oncology.
Black Diamond Therapeutics (Nasdaq: BDTX) announced the formation of Launchpad Therapeutics, an antibody-focused precision oncology company, through a $30 million Series A investment led by Versant Ventures and NEA. Black Diamond contributed early-stage antibody programs and licensed its MAP Drug Discovery Engine to Launchpad, receiving a minority equity stake in return. This strategic move enables Black Diamond to concentrate on its existing drug pipeline while Launchpad aims to leverage advanced computational tools for novel antibody therapies, addressing genetically defined cancers.
Black Diamond Therapeutics, a precision oncology company (Nasdaq: BDTX), will participate in three investor conferences in November and December 2022. The events include the H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference on November 14, the Stifel 2022 Healthcare Conference on November 15, and the Piper Sandler 34th Annual Healthcare Conference on December 1. Each presentation will be available via webcast on the company’s investor relations website for 90 days post-event.
FAQ
What is the current stock price of Black Diamond Therapeutics (BDTX)?
What is the market cap of Black Diamond Therapeutics (BDTX)?
What does Black Diamond Therapeutics do?
Where is Black Diamond Therapeutics headquartered?
What is the Mutation-Allostery-Pharmacology (MAP) platform?
What is BDTX-189?
What are the key clinical-stage programs at Black Diamond?
What recent achievements has Black Diamond Therapeutics made?
What are upcoming milestones for Black Diamond Therapeutics?
What collaborations is Black Diamond involved in?
When was Black Diamond Therapeutics founded?
How does BDTX-1535 differ from existing therapies?
